Bifeprofen

Bifeprofen

SCHEMBL2109705

CC(C(=O)OCC(=O)N1CCN(C)CC1)c1ccc(-c2ccccc2Cl)cc1

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.44
▸ POLB P06746 2/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ KEAP1 Q14145 1/20 0.43
▸ NFE2L2 Q16236 1/20 0.43
▸ KMT2A Q03164 4/20 0.43
▸ GAA P10253 2/20 0.43
▸ TP53 P04637 2/20 0.43
▸ MEN1 O00255 2/20 0.41
▸ USP2 O75604 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ DPP4 P27487 1/20 0.41
▸ DPP7 Q9UHL4 1/20 0.41
▸ ACHE P22303 1/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bifeprofen SCHEMBL10989641 0.99 NFE2L2 (0.45) L3MBTL1POLBTDP1KEAP1NFE2L2
SCHEMBL10980222 0.88 ALDH1A1 (0.50) L3MBTL1NPC1ALDH1A1RAB9AHSD17B10
SCHEMBL10983045 0.84 DPP4 (0.46) L3MBTL1KMT2AGAATP53DPP4
SCHEMBL11125222 0.75 CHRM1 (0.50) L3MBTL1POLBKMT2AGAATP53
Hydrochloric Acid SCHEMBL10990542 0.74 CHRM1 (0.49) L3MBTL1POLBKMT2AGAATP53
SCHEMBL10981141 0.72 PTGS2 (0.66) KMT2AMEN1HPGDTSHR
SCHEMBL9230403 0.71 LMNA (0.57) POLBKMT2AMEN1NPC1KDM4E
SCHEMBL28775715 0.70 SCN9A (0.48) KMT2ADPP4DPP7
SCHEMBL9233581 0.70 RAB9A (0.62) KMT2AGAAMEN1USP2ACHE
SCHEMBL9235386 0.70 RAB9A (0.62) KMT2AGAAMEN1USP2ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118806733-A Hydrogel plaster containing ifenprodil liposome and preparation method thereof 南京海纳医药科技股份有限公司 2024-10-22 — — CN claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 — — EP claimed
US-4510142-A ANTIINFLAMMATORY OR ANALGESIC AGNET PIERRE FABRE S.A. (FR) 1985-04-09 — — US claimed
CN-118806733-A Hydrogel plaster containing ifenprodil liposome and preparation method thereof 南京海纳医药科技股份有限公司 2024-10-22 — — CN disclosed
US-20220047505-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2022-02-17 — — US disclosed
US-11191719-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2021-12-07 — — US disclosed
US-10463611-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2019-11-05 — — US disclosed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US disclosed
US-20140154313-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2014-06-05 — — US disclosed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP disclosed
CN-1319962-C 3-(cyclopenten-1-yl)-benzyl- or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia PF MEDICAMENT (FR) 2007-06-06 — — CN disclosed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO disclosed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US disclosed
CN-1705653-A 3-(cyclopenten-1-yl)-benzyl- or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia PF MEDICAMENT (FR) 2005-12-07 — — CN disclosed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 — — EP disclosed
Send feedback